not losing weight on semaglutide should i switch to tirzepatide vs. for Loss Switching from Semaglutide to Tirzepatide:

However, multiple customers report difficulty with the cancellation process

Aprobado por la FDA en mayo de 2022, este medicamento inyectable funciona como un agonista dual del receptor del polipptido insulinotrpico dependiente de la glucosa (GIP) y del pptido similar al glucagn-1 (GLP-1)

Recent Major Changes Indications and Usage for Zepbound ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition

Electrolyte supplementation helps manage some tirzepatide side effects

It can also be prescribed for its potential to promote weight loss as an off-label use